AAV Vector miRNA Scaffold for Myelin Disorder Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for myelin-related disorders are limited, and there is a need for effective treatments that can address the underlying pathological processes.
Innovation Solution
The use of adeno-associated virus (AAV) particles with preferential tropism for oligodendrocytes, encapsulating a polynucleotide that includes a miRNA scaffold targeting specific genes associated with myelin disorders, to reduce gene expression and treat inherited and acquired disorders of myelin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapies are used for myelin-related disorders, then treatment options are limited, but the underlying pathological processes cannot be effectively addressed
Solution Approach 1:
The invention changes the parameter of gene expression levels by introducing miRNA molecules that specifically target and reduce the expression of pathological genes (such as PLP1 in Pelizaeus-Merzbacher disease). This allows effective treatment by modulating molecular parameters rather than relying on conventional symptomatic therapies.
Solution Approach 2:
The invention uses AAV vectors as intermediaries to deliver therapeutic miRNA molecules to oligodendrocytes. The AAV acts as a mediator that enables targeted gene silencing in specific cell types, bridging the gap between available delivery systems and the need for cell-specific therapy in myelin disorders.
2Reliability
If AAV particles with preferential tropism for oligodendrocytes are used, then gene expression can be reduced in target cells, but the complexity of the treatment increases
Solution Approach 1:
The treatment is segmented into distinct functional components: the AAV capsid (for targeted delivery to oligodendrocytes), the miRNA molecule (for gene silencing), and the expression cassette (for controlled production). This segmentation allows each component to be optimized independently while maintaining overall therapeutic effectiveness.
Solution Approach 2:
The AAV vector system serves multiple functions: it provides targeted delivery to oligodendrocytes through engineered tropism, protects the miRNA cargo during delivery, and enables controlled expression of the therapeutic molecule. This multi-functionality reduces the need for separate delivery and expression systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach potentially reduces the expression of proteins that contribute to myelin disorders, such as Pelizaeus-Merzbacher disease, multiple system atrophy, and Hypomyelination with Atrophy of the Basal Ganglia and Cerebellum, thereby improving treatment outcomes.
Implementation Method 1
providing a composition which comprises an adeno-associated virus (AAV) particle with preferential tropism for the oligodendrocyte cell surface; wherein the AAV particle encapsidates a polynucleotide
Implementation Method 2
the polynucleotide comprises a 5′ inverted terminal repeat (ITR), a promoter sequence region, a polynucleotide encoding a pri- or pre-miRNA targeting said gene
Data Source
AI summary
The present disclosure relates to RNA molecules, recombinant nucleic acids, and gene therapy vectors for use in the treatment of diseases and disorders associated with a deficiency or dysfunction of myelin.